ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
62 952,38
0,10%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Indaptus Therapeutics Inc (INDP)

  7. Indaptus Therapeutics Inc (INDP) Actualités

INDP Indaptus Therapeutics Inc

2,02
0,015 (0,75%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Indaptus Therapeutics Inc INDP NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,015 0,75% 2,02 22:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,02 2,00 2,11 2,02 2,005
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/4/202413:30GLOBEIndaptus Therapeutics Presents Positive Mechanism of Action..
28/3/202413:00GLOBEIndaptus Therapeutics to Present at the MedInvest Biotech..
25/3/202413:30GLOBEIndaptus Therapeutics Previews Positive Mechanism of Action..
18/3/202413:00GLOBEIndaptus Therapeutics to Participate in Tribe Public Webinar..
13/3/202412:30GLOBEIndaptus Therapeutics Reports Fourth Quarter and Year-End..
04/3/202417:01EDGAR2Form 8-K - Current report
04/3/202413:30GLOBEIndaptus Therapeutics Announces Positive Results from Second..
15/2/202414:00GLOBEIndaptus Therapeutics to Present at the 2024 BIO CEO &..
08/2/202414:00GLOBEIndaptus Therapeutics Expands Digital Presence with Launch..
23/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202422:05EDGAR2Form 8-K - Current report
04/1/202414:00GLOBEEuropean Patent Office Approves Key Patent for Indaptus..
06/11/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:05EDGAR2Form 8-K - Current report
06/11/202322:01GLOBEIndaptus Therapeutics Reports Third Quarter 2023 Financial..
06/11/202314:13EDGAR2Form 8-K - Current report
06/11/202314:00GLOBEIndaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune..
31/10/202314:12EDGAR2Form 8-K - Current report
31/10/202314:01GLOBEIndaptus Therapeutics to Present Positive Pharmacodynamic..
27/9/202314:00GLOBEIndaptus Therapeutics to Present at the LD Micro Main Event..
26/9/202314:00GLOBERegistration Is Now Open For Tribe Public’s Webinar Event..
19/9/202314:00GLOBEIndaptus Therapeutics Doses First Patient in Second Cohort..
06/9/202314:05GLOBEIndaptus Therapeutics to Present at the H.C. Wainwright 25th..
17/8/202300:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202314:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202314:10EDGAR2Form 8-K - Current report
14/8/202314:00GLOBEIndaptus Therapeutics Reports Second Quarter 2023 Financial..
10/8/202314:45EDGAR2Form 8-K - Current report
10/8/202314:45GLOBEIndaptus Therapeutics Announces Opening of Next Cohort in..
07/8/202314:00GLOBEIndaptus Therapeutics Appoints Industry Veteran Roger..
15/6/202314:00GLOBEIndaptus Therapeutics to Participate in the Maxim Group..
31/5/202314:30GLOBEIndaptus Therapeutics to Present at the Jefferies Healthcare..
11/5/202313:00GLOBEIndaptus Therapeutics Reports First Quarter 2023 Financial..
09/5/202314:00GLOBEFollowing Granting of Indian Patent, Indaptus Therapeutics..

Dernières Valeurs Consultées

NASDAQ
INDP
Indaptus Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés